Suven Pharmaceuticals Limited
SUVENPHAR.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$412.41B
Close$
$252.81
76.5% downside
Current Fair Value
76.5% downsideOvervalued by 76.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $412.41 Billion |
|---|---|
| Enterprise Value | $412.41 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $10.52 |
| Beta | 1.13 |
| Outstanding Shares | 384,881,889 |
Return
| Return on Equity | 13.73% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 104.5 |
|---|---|
| PEG | -534.11 |
| Price to Sales | 27.64 |
| Price to Book Ratio | 22.94 |
| Enterprise Value to Revenue | 27.2 |
| Enterprise Value to EBIT | 121.85 |
| Enterprise Value to Net Income | 163 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cohance Lifesciences Limited
2,576 employees
CEO: Umang Vohra Headquartered in Hyderabad, Cohance Lifesciences Limited is a pharmaceutical company with a core focus on providing contract development and manufacturing (CDMO) services, developing active pharmaceutical ingredients (APIs), and manufact...